🔴 Hims & Hers Health is trading 18% down today ahead of a pivotal FDA review on peptide compounding

Hims & Hers Health is trading at €25.18 (-17.98%) as investors weigh regulatory risks ahead of a key FDA advisory committee meeting regarding the company’s peptide expansion plans.

• The FDA Pharmacy Compounding Advisory Committee is scheduled to meet July 23-24 to review whether seven specific peptides should be added to the approved compounding list.
• The sharp decline suggests the market is pricing in regulatory uncertainty and a potential setback for a thesis that relied on a favorable expansion of the company's product offerings.
• A positive outcome from the committee would have opened a significant growth opportunity, making this meeting a critical catalyst for the stock.